Takeda Gets Japanese Approval for $62 Billion Shire Purchase

Source: Reuters

Takeda Pharmaceutical reported that Japan’s Fair Trade Commission had approved its $62 billion acquisition of Shire, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker, according to Reuters.

The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from regulators in the United States, Brazil, and China.

“Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly innovative medicines that are transformative to patients in Japan and around the world,” Takeda CEO Christophe Weber said in a statement.

Read the full article.

Related Content